Senti Biosciences reported Q2 2024 financial results with a net loss of $11.2 million ($2.45 per share). The company held cash and cash equivalents of $15.9 million as of June 30, 2024, with an additional $18.9 million in receivables expected from the GeneFab transaction. R&D expenses increased to $9.2 million from $6.9 million YoY, while G&A expenses decreased to $4.2 million from $9.2 million.The company announced an $8 million grant from the California Institute for Regenerative Medicines to support the clinical development of SENTI-202, a Logic Gated CAR-NK cell therapy for relapsed/refractory hematologic malignancies including AML. Patient dosing is ongoing in the Phase 1 trial, with initial efficacy data expected by year-end 2024 and durability data in 2025.Additionally, Senti Bio regained Nasdaq compliance after maintaining a minimum bid price of $1.00 for 10 consecutive business days. The company's partnership with Celest Therapeutics for SENTI-301A development in HCC is progressing, with first patient dosing expected in Q4 2024 in mainland China.

Senti Biosciences reported Q2 2024 financial results with a net loss of $11.2 million ($2.45 per share). The company held cash and cash equivalents of $15.9 million as of June 30, 2024, with an additional $18.9 million in receivables expected from the GeneFab transaction. R&D expenses increased to $9.2 million from $6.9 million YoY, while G&A expenses decreased to $4.2 million from $9.2 million.The company announced an $8 million grant from the California Institute for Regenerative Medicines to support the clinical development of SENTI-202, a Logic Gated CAR-NK cell therapy for relapsed/refractory hematologic malignancies including AML. Patient dosing is ongoing in the Phase 1 trial, with initial efficacy data expected by year-end 2024 and durability data in 2025.Additionally, Senti Bio regained Nasdaq compliance after maintaining a minimum bid price of $1.00 for 10 consecutive business days. The company's partnership with Celest Therapeutics for SENTI-301A development in HCC is progressing, with first patient dosing expected in Q4 2024 in mainland China.